169
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity

, , , , &
Pages 443-449 | Received 13 May 2020, Accepted 08 Mar 2021, Published online: 19 Apr 2021

References

  • Almaani, S., Meara, A., and Rovin, B.H., 2017. Update on lupus nephritis. Clinical journal of the american society of nephrology, 12 (5), 825–835.
  • Backes, Y., et al., 2012. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive care medicine, 38 (9), 1418–1418.
  • Banchereau, R., et al., 2016. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell, 165 (3), 551–565.
  • Dessapt, C., et al., 2009. Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation. Nephrology, dialysis, transplantation, 24 (9), 2645–2655.
  • Gladman, D.D., Ibañez, D., and Urowitz, M.B., 2002. Systemic lupus erythematosus diseaseactivity index 2000. The journal of rheumatology, 29 (2), 288–291.
  • Griffiths, B., Mosca, M., and Gordon, C., 2005. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best practice & research Clinical rheumatology, 19 (5), 685–708.
  • Guo, S.M., et al., 2015. Soluble urokinase receptor levels are correlated with focal segmental glomerulosclerosis lesions in IgA nephropathy: a cohort study from China. PLoS one, 10 (9), e0138718.
  • Hamie, L., et al., 2018. SuPAR, an emerging biomarker in kidney and inflammatory diseases. Postgraduate medical journal, 94 (1115), 517–524.
  • Hayek, S.S., Sever, S., et al., 2015. Soluble urokinase receptor and chronic kidney. New England journal of medicine, 373 (20), 1916–1925.
  • Martin, M., et al., 2017. Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus. Arthritis research & therapy, 19 (1), 266.
  • Mundel, P., and Reiser, J., 2010. Proteinuria: an enzymatic disease of the podocyte? Kidney international, 77 (7), 571–580.
  • Petri, M., et al., 2012. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis & rheumatism, 64 (8), 2677–2686.
  • Reiser, J., and Sever, S., 2013. Podocyte biology and pathogenesis of kidney disease. Annual review of medicine, 64, 357–366.
  • Rezende, G.M., et al., 2014. Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlyingmechanisms of proteinuria? Lupus, 23 (3), 255–262.
  • Sakhi, H., et al., 2019. Podocyte injury in lupus nephritis. Journal of clinical medicine, 8 (9), 1340.
  • Szeto, C.C., 2017. Urinary mRNA and lupus disease flare. Nephrology, 22, 27–30.
  • Tektonidou, M.G., Dasgupta, A., and Ward, M.M., 2016. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and bayesian meta-analysis. Arthritis & rheumatology , 68 (6), 1432–1441.
  • Thunø, M., Macho, B., and Eugen-Olsen, J., 2009. suPAR: the molecular crystal ball. Disease markers, 27 (3), 157–172.
  • Toldi, G., et al., 2012. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus. Biomarkers, 17 (8), 758–763.
  • Turnier, J.L., et al., 2017. Urine S100 proteins as potential biomarkers of lupus nephritis activity. Arthritis research & therapy, 19 (1), 242.
  • Ugarte-Gil, M.F., González, L.A., and Alarcón, G.S., 2019. Lupus Lupus: the new epidemic. Lupus, 28 (9), 1031–1050.
  • Vasarhelyi, B., Toldi, G., and Balog, A., 2016. The clinical value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) levels in autoimmune connective tissue disorders. EJIFCC, 27 (2), 122–129.
  • Wang, Y., et al., 2014. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. Rheumatology, 53 (7), 1235–1244.
  • Weening, J.J., et al., 2004. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney international, 65 (2), 521–523.
  • Wei, C., et al., 2008. Modification of kidney barrier function by the urokinase receptor. Nature medicine, 14 (1), 55–63.
  • Wei, C., et al., 2011. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nature medicine, 17 (8), 952–960.
  • Wu, C.Z., et al., 2015. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy. Clinical biochemistry, 48 (18), 1324–1329.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.